48 research outputs found

    Therapeutic Angiogenesis: Foundations and Practical Application

    Get PDF
    Angiogenesis as therapeutic target has emerged since early works by Judah Folkman, yet his β€œholy grail” was inhibiting vascular growth to block tumor nutrition. However, in modern biomedicine, β€œtherapeutic angiogenesis” became a large field focusing on stimulation of blood vessel growth for ischemia relief to reduce its detrimental effects in the tissues. In this review, we introduce basic principles of tissue vascularization in response to ischemia exploited in this field. An overview of recent status in therapeutic angiogenesis is given with introduction to emerging technologies, including gene therapy, genetic modification of cells ex vivo and tissue engineering

    Oligonucleotide Microarrays Identified Potential Regulatory Genes Related to Early Outward Arterial Remodeling Induced by Tissue Plasminogen Activator

    Get PDF
    Constrictive vascular remodeling limiting blood flow, as well as compensatory outward remodeling, has been observed in many cardiovascular diseases; however, the underlying mechanisms regulating the remodeling response of the vessels remain unclear. Plasminogen activators (PA) are involved in many of the processes of vascular remodeling. We have shown previously that increased levels of tissue-type PA (tPA) contributes to outward vascular remodeling. To elucidate the mechanisms involved in the induction of outward remodeling we characterized changes in the expression profiles of 8799 genes in injured rat carotid arteries 1 and 4 days after recombinant tPA treatment compared to vehicle. Periadventitial tPA significantly increased lumen size and vessel area, encompassed by the external elastic lamina, at both one and 4 days after treatment. Among 41 differentially expressed known genes 1 day after tPA application, five genes were involved in gene transcription, five genes were related to the regulation of vascular tone [for example, thromboxane A2 receptor (D32080) or non-selective-type endothelin receptor (S65355)], and eight genes were identified as participating in vascular innervation [for example, calpain (D14478) or neural cell adhesion molecule L1 (X59149)]. Four days after injury in tPA-treated arteries, four genes, regulating vascular tone, were differentially expressed. Thus, tPA promotes outward arterial remodeling after injury, at least in part, by regulating expression of genes in the vessel wall related to function of the nervous system and vascular tone

    Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression

    Get PDF
    Urokinase-type plasminogen activator (uPA) regulates angiogenesis and vascular permeability through proteolytic degradation of extracellular matrix and intracellular signaling initiated upon its binding to uPAR/CD87 and other cell surface receptors. Here, we describe an additional mechanism by which uPA regulates angiogenesis. Ex vivo VEGF-induced vascular sprouting from Matrigel-embedded aortic rings isolated from uPA knock-out (uPA(βˆ’/βˆ’)) mice was impaired compared with vessels emanating from wild-type mice. Endothelial cells isolated from uPA(βˆ’/βˆ’) mice show less proliferation and migration in response to VEGF than their wild type counterparts or uPA(βˆ’/βˆ’) endothelial cells in which expression of wild type uPA had been restored. We reported previously that uPA is transported from cell surface receptors to nuclei through a mechanism that requires its kringle domain. Intranuclear uPA modulates gene transcription by binding to a subset of transcription factors. Here we report that wild type single-chain uPA, but not uPA variants incapable of nuclear transport, increases the expression of cell surface VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) by translocating to the nuclei of ECs. Intranuclear single-chain uPA binds directly to and interferes with the function of the transcription factor hematopoietically expressed homeodomain protein or proline-rich homeodomain protein (HHEX/PRH), which thereby lose their physiologic capacity to repress the activity of vehgr1 and vegfr2 gene promoters. These studies identify uPA-dependent de-repression of vegfr1 and vegfr2 gene transcription through binding to HHEX/PRH as a novel mechanism by which uPA mediates the pro-angiogenic effects of VEGF and identifies a potential new target for control of pathologic angiogenesis

    UK–Russia Researcher Links Workshop: extracellular vesicles – mechanisms of biogenesis and roles in disease pathogenesis, M.V. Lomonosov Moscow State University, Moscow, Russia, 1–5 March 2015

    Get PDF
    The UK–Russia extracellular vesicles (EVs) workshop was held at the Medical Center of the M.V. Lomonosov Moscow State University, Moscow, Russia, with 56 attendees from UK and Russian universities and research institutes. The program consisted of 6 research sessions and was focused on studies of EVs isolated from in vitro model systems or biological fluids, including blood and urine. The multidisciplinary program included presentations on mechanisms of EV biogenesis, the role of EVs in disease pathogenesis, the diagnostic value of EVs, including their quantitation and cargo load, as well as the clinical use of EVs in regenerative medicine. Methodological challenges imposed by the nanoscale size of EVs as well as targeted delivery approaches for therapeutics were considered in a separate session on technologies. The main aim of the workshop was to overview challenges confronting EV researchers and to facilitate knowledge exchange between researchers with different backgrounds and skills. Given the lack of definitive EV nomenclature, specific terms (exosomes or microvesicles) were only applied in the meeting report to studies that carried out full EV characterization, including differential ultracentrifugation isolation approaches, comprehensive protein marker characterization, and single vesicle analysis (electron microscopy and nanoparticle analysis), to ascertain EV size and morphology following the International Society for Extracellular Vesicles standardization recommendations (1,2). In studies where characterization was not conclusive, the term EV is used

    Π­ΠΏΠΈΠΊΠ°Ρ€Π΄ΠΈΠ°Π»ΡŒΠ½Π°Ρ трансплантация пластов ΠΈΠ· ΠΌΠ΅Π·Π΅Π½Ρ…ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… ΡΡ‚Ρ€ΠΎΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΆΠΈΡ€ΠΎΠ²ΠΎΠΉ ΠΊΠ»Π΅Ρ‚Ρ‡Π°Ρ‚ΠΊΠΈ способствуСт Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΠΈ эпикарда ΠΈ стимулируСт Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π· ΠΏΡ€ΠΈ ΠΈΠ½Ρ„Π°Ρ€ΠΊΡ‚Π΅ ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π° (ΡΠΊΡΠΏΠ΅Ρ€ΠΈΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½ΠΎΠ΅ исслСдованиС)

    Get PDF
    Aim: to evaluate the impact of tissue-engineered structures (TES) transplantation based on mesenchymal stromal cell (MSC) sheets in myocardial infarction on the activation of the epicardial cell pool and vascularization of the damaged zone.Materials and methods. Mesenchymal stromal cells were obtained from samples of subcutaneous fat of Wistar rats and C57Bl/6 mice. Tissue engineering structures were obtained by culturing cell sheets on thermosensitive plates (Nunc Dishes with UpCell Surface). Transplantation of TESs was performed after myocardial infarction modeling in rats by ligation of the anterior descending coronary artery. Transplant cells and damaged zones were assessed using immunofluorescent staining of myocardial cryosections. The impact of MSC secretion products on the migration activity of epicardial cells in vitro was evaluated using the explant culture method.Results. MSCs in TESs after transplantation remain viable and induce activation of the epicardial cell pool and local increase of the damaged zone vascularization. The in vitro experiments showed that the conditioned environment of MSCs stimulates the migratory activity of epicardial cells and initiates the formation of activated Wt1/POD1 precursor cells.Conclusion. TES transplantation on the basis of MSC sheets seems to be a promising approach for effective delivery of viable cells into myocardium to activate the epicardial cellular niche and reparative angiogenesis.ЦСль исслСдования: ΠΎΡ†Π΅Π½ΠΈΡ‚ΡŒ влияниС трансплантации Ρ‚ΠΊΠ°Π½Π΅ΠΈΠ½ΠΆΠ΅Π½Π΅Ρ€Π½Ρ‹Ρ… конструкций (ВИК) Π½Π° основС пластов ΠΌΠ΅Π·Π΅Π½Ρ…ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… ΡΡ‚Ρ€ΠΎΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ (МБК) ΠΏΡ€ΠΈ ΠΈΠ½Ρ„Π°Ρ€ΠΊΡ‚Π΅ ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π° Π½Π° Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΡŽ ΡΠΏΠΈΠΊΠ°Ρ€Π΄ΠΈΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΏΡƒΠ»Π° ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΈ Π²Π°ΡΠΊΡƒΠ»ΡΡ€ΠΈΠ·Π°Ρ†ΠΈΡŽ Π·ΠΎΠ½Ρ‹ поврСТдСния.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. МБК ΠΏΠΎΠ»ΡƒΡ‡ΠΈΠ»ΠΈ ΠΈΠ· ΠΎΠ±Ρ€Π°Π·Ρ†ΠΎΠ² ΠΏΠΎΠ΄ΠΊΠΎΠΆΠ½ΠΎΠΉ ΠΆΠΈΡ€ΠΎΠ²ΠΎΠΉ ΠΊΠ»Π΅Ρ‚Ρ‡Π°Ρ‚ΠΊΠΈ крыс Π»ΠΈΠ½ΠΈΠΈ Wistar ΠΈ ΠΌΡ‹ΡˆΠ΅ΠΉ Π»ΠΈΠ½ΠΈΠΈ C57Bl/6. ВИК ΠΏΠΎΠ»ΡƒΡ‡ΠΈΠ»ΠΈ ΠΏΡƒΡ‚Π΅ΠΌ ΠΊΡƒΠ»ΡŒΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΡ пластов ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π½Π° Ρ‡Π°ΡˆΠΊΠ°Ρ… с Ρ‚Π΅Ρ€ΠΌΠΎΡ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ ΠΏΠΎΠΊΡ€Ρ‹Ρ‚ΠΈΠ΅ΠΌ (Nunc Dishes with UpCell Surface). Π’Ρ€Π°Π½ΡΠΏΠ»Π°Π½Ρ‚Π°Ρ†ΠΈΡŽ ВИК ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ послС модСлирования ΠΈΠ½Ρ„Π°Ρ€ΠΊΡ‚Π° ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π° Ρƒ крысы ΠΏΡƒΡ‚Π΅ΠΌ пСрСвязки ΠΏΠ΅Ρ€Π΅Π΄Π½Π΅ΠΉ нисходящСй ΠΊΠΎΡ€ΠΎΠ½Π°Ρ€Π½ΠΎΠΉ Π°Ρ€Ρ‚Π΅Ρ€ΠΈΠΈ. ΠžΡ†Π΅Π½ΠΊΡƒ состояния ΠΊΠ»Π΅Ρ‚ΠΎΠΊ трансплантата ΠΈ Π·ΠΎΠ½Ρ‹ поврСТдСния ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ с использованиСм иммунофлуорСсцСнтного ΠΎΠΊΡ€Π°ΡˆΠΈΠ²Π°Π½ΠΈΡ криосрСзов ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π°. Для ΠΎΡ†Π΅Π½ΠΊΠΈ влияния ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² сСкрСции МБК Π½Π° ΠΌΠΈΠ³Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΡƒΡŽ Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΊΠ»Π΅Ρ‚ΠΎΠΊ эпикарда in vitro использовали ΠΌΠ΅Ρ‚ΠΎΠ΄ эксплантной ΠΊΡƒΠ»ΡŒΡ‚ΡƒΡ€Ρ‹.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. МБК Π² составС ВИК послС трансплантации ΡΠΎΡ…Ρ€Π°Π½ΡΡŽΡ‚ ΠΆΠΈΠ·Π½Π΅ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡ‚ΡŒ ΠΈ Π²Ρ‹Π·Ρ‹Π²Π°ΡŽΡ‚ Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΡŽ ΡΠΏΠΈΠΊΠ°Ρ€Π΄ΠΈΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΏΡƒΠ»Π° ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΈ локальноС ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ васкуляризации Π·ΠΎΠ½Ρ‹ поврСТдСния. ЭкспСримСнты in vitro ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, Ρ‡Ρ‚ΠΎ кондиционированная срСда МБК ΠΎΠΊΠ°Π·Ρ‹Π²Π°Π΅Ρ‚ ΡΡ‚ΠΈΠΌΡƒΠ»ΠΈΡ€ΡƒΡŽΡ‰Π΅Π΅ воздСйствиС Π½Π° ΠΌΠΈΠ³Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΡƒΡŽ Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΊΠ»Π΅Ρ‚ΠΎΠΊ эпикарда ΠΈ Π²Ρ‹Π·Ρ‹Π²Π°Π΅Ρ‚ ΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ Π°ΠΊΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… Wt1/POD1 ΠΊΠ»Π΅Ρ‚ΠΎΠΊ-ΠΏΡ€Π΅Π΄ΡˆΠ΅ΡΡ‚Π²Π΅Π½Π½ΠΈΡ†.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Врансплантация ВИК Π½Π° основС пластов МБК прСдставляСтся Ρ€Π°Ρ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½Ρ‹ΠΌ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ΠΎΠΌ для эффСктивной доставки ТизнСспособных ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π² ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄ с Ρ†Π΅Π»ΡŒΡŽ Π°ΠΊΡ‚ΠΈΠ²ΠΈΡ€ΡƒΡŽΡ‰Π΅Π³ΠΎ воздСйствия Π½Π° ΡΠΏΠΈΠΊΠ°Ρ€Π΄ΠΈΠ°Π»ΡŒΠ½ΡƒΡŽ ΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½ΡƒΡŽ Π½ΠΈΡˆΡƒ ΠΈ Ρ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΈΠ²Π½Ρ‹ΠΉ Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·

    Combined Transfer of Human VEGF165 and HGF Genes Renders Potent Angiogenic Effect in Ischemic Skeletal Muscle

    Get PDF
    Increased interest in development of combined gene therapy emerges from results of recent clinical trials that indicate good safety yet unexpected low efficacy of β€œsingle-gene” administration. Multiple studies showed that vascular endothelial growth factor 165 aminoacid form (VEGF165) and hepatocyte growth factor (HGF) can be used for induction of angiogenesis in ischemic myocardium and skeletal muscle. Gene transfer system composed of a novel cytomegalovirus-based (CMV) plasmid vector and codon-optimized human VEGF165 and HGF genes combined with intramuscular low-voltage electroporation was developed and tested in vitro and in vivo. Studies in HEK293T cell culture, murine skeletal muscle explants and ELISA of tissue homogenates showed efficacy of constructed plasmids. Functional activity of angiogenic proteins secreted by HEK293T after transfection by induction of tube formation in human umbilical vein endothelial cell (HUVEC) culture. HUVEC cells were used for in vitro experiments to assay the putative signaling pathways to be responsible for combined administration effect one of which could be the ERK1/2 pathway. In vivo tests of VEGF165 and HGF genes co-transfer were conceived in mouse model of hind limb ischemia. Intramuscular administration of plasmid encoding either VEGF165 or HGF gene resulted in increased perfusion compared to empty vector administration. Mice injected with a mixture of two plasmids (VEGF165+HGF) showed significant increase in perfusion compared to single plasmid injection. These findings were supported by increased CD31+ capillary and SMA+ vessel density in animals that received combined VEGF165 and HGF gene therapy compared to single gene therapy. Results of the study suggest that co-transfer of VEGF and HGF genes renders a robust angiogenic effect in ischemic skeletal muscle and may present interest as a potential therapeutic combination for treatment of ischemic disorders

    Adipose-Derived Stem Cells Stimulate Regeneration of Peripheral Nerves: BDNF Secreted by These Cells Promotes Nerve Healing and Axon Growth De Novo

    Get PDF
    Transplantation of adipose-derived mesenchymal stem cells (ASCs) induces tissue regeneration by accelerating the growth of blood vessels and nerve. However, mechanisms by which they accelerate the growth of nerve fibers are only partially understood. We used transplantation of ASCs with subcutaneous matrigel implants (well-known in vivo model of angiogenesis) and model of mice limb reinnervation to check the influence of ASC on nerve growth. Here we show that ASCs stimulate the regeneration of nerves in innervated mice's limbs and induce axon growth in subcutaneous matrigel implants. To investigate the mechanism of this action we analyzed different properties of these cells and showed that they express numerous genes of neurotrophins and extracellular matrix proteins required for the nerve growth and myelination. Induction of neural differentiation of ASCs enhances production of brain-derived neurotrophic factor (BDNF) as well as ability of these cells to induce nerve fiber growth. BDNF neutralizing antibodies abrogated the stimulatory effects of ASCs on the growth of nerve sprouts. These data suggest that ASCs induce nerve repair and growth via BDNF production. This stimulatory effect can be further enhanced by culturing the cells in neural differentiation medium prior to transplantation
    corecore